Prostate cancer is the leading cancer in males in the US. An estimated 174,000 new cases are diagnosed each year.
Up to 10% of patients with metastatic or advanced prostate cancer and 3% of patients with localized prostate cancer carry a disease-causing variant in a DNA repair gene and other genes conferring risk for hereditary cancer disorders.
Determining the germline genetic etiology of prostate cancer provides eligibility for precision medical and surgical treatment options and eligibility to participate in clinical trials. It enables surveillance for, and early detection of, other DNA repair-related cancers, and identification of risk and surveillance recommendations for early detection in at-risk relatives.
Gleason score of 6 or less: age at diagnosis 55 years or under AND clinically suspected low risk
Gleason score of 7 or greater at any age
All metastatic patients
Gleason score undetermined, suspected low risk (stage IIa) or above at any age
Stage IIa, age at diagnosis 55 years or under
Stage IIb or IIc at any age
Stage III at any age
Stage IV, including metastatic, at any age
Clinicians can place an order by following the steps below (please note that the Detect Hereditary Prostate Cancer program only accepts paper orders).
To receive results:
If you're a patient and believe you are eligible for this sponsored testing program, you have options:
Contact Genome Medical
(available in US only)
Schedule a genetic counseling session, by phone or video, with an expert who can review your testing options and place the order. There is a cost associated with the Genome Medical services, which may be covered under your health benefits.
Discuss the program with your doctor
If you already have a healthcare provider who can place this order, you can download this flyer to take to your own provider.
Find a local genetics provider
Search our genetics providers network to find a provider in your area. Please sign in, or create an account, to connect with our network of professionals. There may be a cost associated with the provider’s services.
Commitment to quality:
Invitae’s >1000 patient peer-reviewed study, published in the Journal Molecular Diagnostics, the official journal of the Association for Molecular Pathology, shows equivalence to established standards.
Sample options: blood and saliva kits provided free of charge.
Strong team: Invitae has more than 300 experts in genetics, bioinformatics, engineering, technology, and commercial development.
Invitae is a genetic information company whose mission is to bring genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene tests today.
While third parties and commercial organizations may provide financial support for this program, tests and services are performed by Invitae. Healthcare professionals must confirm that patients meet certain criteria to use the program. Third parties and commercial organizations may receive de-identified patient data from this program, but at no time would they receive patient identifiable information. Third parties and commercial organizations may receive contact information for healthcare professionals who use this program. Genetic testing and counseling are available in the US and Canada. Healthcare professionals and patients who participate in this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any other products or services from Invitae or from third parties or commercial organizations.